NASDAQ: CLNN · Life Sciences · 5 alerts · CIK 1822791
Share price
$3.66Close, Nov 16
Market cap
$52.7M
Shares outstanding
14.4MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Clene Inc. filings on SEC EDGAR ↗
Clene Inc. reported on its warrant status as of September 30, 2026, noting that Tranche A Warrants expired unexercised in June 2026, while Tranche B and 2024 Common Warrants remain outstanding with no exercises to date. The company continues to manage various debt instruments, including notes payable and convertible notes, while recording expenses related to R&D and general administrative operations.
Clene Inc. reported third quarter 2026 financial results, highlighting the submission of a New Drug Application (NDA) to the FDA for CNM-Au8 in ALS. The company ended the quarter with $9.9 million in cash, bolstered by a $4.0 million registered direct offering completed in September, providing a runway through mid-first quarter 2027.
“Clene’s submission of the NDA for CNM-Au8 is a pivotal achievement for the company and, more importantly, a meaningful step toward bringing new treatment options to people living with ALS. People living with ALS urgently need additional treatment options, and we appreciate the FDA’s constructive engagement throughout this process. We look forward to working closely with the Agency during its pending review. We believe CNM-Au8 has the capacity to restore and protect neuronal health and function and improve survival.”
Clene Inc. entered into a subaward amendment with NYU for the fourth year of a previously announced NIH grant, providing up to $7.2 million in funding. The grant supports an Expanded Access Program for the company's CNM-Au8 treatment for amyotrophic lateral sclerosis (ALS). This represents the final year of a total $45.1 million four-year grant awarded under the ACT for ALS Act.
Clene Inc. has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS). The submission is based on neurofilament light chain biomarker data and clinical outcomes, with the company also preparing for a confirmatory Phase 3 RESTORE-ALS study.